價(jià)格 | ¥501.90 |
包裝 | 1ml |
最小起訂量 | 1ml |
發(fā)貨地 | 上海 |
文件下載 | 檢測(cè)報(bào)告COA |
更新日期 | 2025-02-27 |
中文名稱:Darifenacin HBr | 英文名稱:Darifenacin HBr |
CAS:133099-07-7 | 品牌: 阿拉丁 |
產(chǎn)地: 上海 | 保存條件: -80℃儲(chǔ)存 |
純度規(guī)格: 10mM in DMSO | 產(chǎn)品類別: 藥靶配體 藥靶配體 |
分子式: C28H30N2O2·HBr | 分子量: 507.46 |
運(yùn)輸條件: 超低溫冰袋運(yùn)輸 | 產(chǎn)品規(guī)格: 1ml |
貨號(hào): D407822 | 是否進(jìn)口: 否 |
中文名:Darifenacin HBr
英文名:Darifenacin HBr
英文別名:UK-88525;(S)-3-(Carbamoyldiphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]pyrrolidine hydrobromide
純度:10mM in DMSO
貨號(hào):D407822
包裝:1ml
Cas號(hào):133099-07-7
存儲(chǔ)溫度:-80℃儲(chǔ)存
產(chǎn)品介紹:
Information
Darifenacin HBr (UK-88525) is a selectiveM3 muscarinicreceptor antagonist withpKiof 8.9.
In?vitro
Darifenacin exerts non-parallel rightward displacement of the agonist curve and also significant depression of the maximum response (+)-cis-Dioxolane produced concentration-dependent contraction of the isolated bladder of rat. Darifenacin produces a concentration dependent increase in R123 (P-gp probe) accumulation in MDCK cells. Darifenacin stimulates ATPase activity in P-gp membrane in a clear concentration dependent response manner with an estimated ED50 value of 1.6\u2009μM. Darifenacin (100 nM) shows a significantly greater permeability for darifenacin in the basolateral to apical direction resulting in an efflux ratio in BBMEC monolayers of approximately 2.6.
In?vivo
Darifenacin produces dose-dependent inhibition of amplitude of volume-induced bladder contractions(VIBCAMP), producing 35% inhibition at dose of 283.3 nmol/kg and maximal inhibition of approximately 50–55%. Darifenacin (0.1 mg/kg i.v.) reduces bladder afferent activity in both Aδ and C fibers in female Sprague-Dawley rats, the decrease in afferent spikes in C fibers may be more pronounced than that in Aδ fibers. Darifenacin (7.5 mg and 15 mg, daily) reduces the number of incontinence episodes per week from baseline by 67.7% and 72.8% respectively compared with 55.9% with placebo in patients with overactive bladder (OAB). Darifenacin (7.5 mg and 15 mg, daily) also shows significantly superior to placebo for improvements in micturition frequency, bladder capacity, frequency of urgency, severity of urgency and number of incontinence episodes leading to a change in clothing or pads in patients with overactive bladder (OAB).
Cell?Data
cell?lines:
Concentrations:
Incubation?Time:
Powder?Purity:≥99%
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對(duì)應(yīng)頁(yè)面:https://www.aladdin-e.com/zh_cn/D407822.html
成立日期 | 2009-03-16 (17年) | 注冊(cè)資本 | 14130.676萬(wàn)人民幣 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 生物化工,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
普善實(shí)業(yè)(陜西)有限公司
|
2025-04-03 | |
¥1500 |
VIP6年
|
湖北阡陌生物科技有限公司
|
2025-04-03 | |
¥5000 |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2025-04-03 | |
¥3800 |
VIP5年
|
湖北眾善奉行醫(yī)藥科技有限公司
|
2025-03-31 | |
¥32.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-03-24 | |
¥255 |
VIP12年
|
上海陶術(shù)生物科技有限公司
|
2025-03-12 | |
¥9900 |
VIP7年
|
陜西締都醫(yī)藥化工有限公司
|
2025-03-06 | |
詢價(jià) |
VIP4年
|
湖北辰心藥業(yè)有限公司
|
2025-02-19 | |
詢價(jià) |
北京邁瑞凱醫(yī)藥科技有限公司
|
2019-10-30 | ||
詢價(jià) |
山東健豐醫(yī)藥化工有限公司
|
2019-10-30 |